Literature DB >> 7579500

Expression of messenger RNA for amphiregulin, heregulin, and cripto-1, three new members of the epidermal growth factor family, in human breast carcinomas.

N Normanno1, N Kim, D Wen, K Smith, A L Harris, G Plowman, G Colletta, F Ciardiello, D S Salomon.   

Abstract

The expression of amphiregulin (AR), heregulin (HRG), and cripto-1 (CR-1) mRNA transcripts was assessed in 60 human primary breast carcinoma. AR and HRG transcripts were expressed respectively in 58% and 25% of the carcinomas as measured by Northern blot analysis. CR-1 mRNA was found in 77% of the carcinomas using Reverse Transcriptase-PCR analysis. Coexpression of two or three of these peptides was observed in several specimens. There was no significant association between AR, HRG, and CR-1 expression and nodal status, EGF receptor, or c-erbB-2 protooncogene expression in these tumors. However, a significant association between AR expression and estrogen receptor positivity was observed.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7579500     DOI: 10.1007/BF00665981

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  8 in total

1.  Expression of amphiregulin, cripto-1, and heregulin-alpha in human breast-cancer cells.

Authors:  N Normanno; C Qi; W Gullick; G Persico; Y Yarden; D Wen; G Plowman; N Kenney; G Johnson; N Kim; R Brandt; I Martinezlacaci; R Dickson; D Salomon
Journal:  Int J Oncol       Date:  1993-06       Impact factor: 5.650

2.  Amphiregulin, epidermal growth factor receptor, and estrogen receptor expression in human primary breast cancer.

Authors:  S LeJeune; R Leek; E Horak; G Plowman; M Greenall; A L Harris
Journal:  Cancer Res       Date:  1993-08-01       Impact factor: 12.701

3.  Neu differentiation factor (heregulin) induces expression of intercellular adhesion molecule 1: implications for mammary tumors.

Authors:  S S Bacus; A V Gudkov; C R Zelnick; D Chin; R Stern; I Stancovski; E Peles; N Ben-Baruch; H Farbstein; R Lupu
Journal:  Cancer Res       Date:  1993-11-01       Impact factor: 12.701

4.  Identification of heregulin, a specific activator of p185erbB2.

Authors:  W E Holmes; M X Sliwkowski; R W Akita; W J Henzel; J Lee; J W Park; D Yansura; N Abadi; H Raab; G D Lewis
Journal:  Science       Date:  1992-05-22       Impact factor: 47.728

5.  The amphiregulin gene encodes a novel epidermal growth factor-related protein with tumor-inhibitory activity.

Authors:  G D Plowman; J M Green; V L McDonald; M G Neubauer; C M Disteche; G J Todaro; M Shoyab
Journal:  Mol Cell Biol       Date:  1990-05       Impact factor: 4.272

Review 6.  Epidermal growth factor-related peptides in the pathogenesis of human breast cancer.

Authors:  N Normanno; F Ciardiello; R Brandt; D S Salomon
Journal:  Breast Cancer Res Treat       Date:  1994-01       Impact factor: 4.872

7.  Amphiregulin as an autocrine growth factor for c-Ha-ras- and c-erbB-2-transformed human mammary epithelial cells.

Authors:  N Normanno; M P Selvam; C F Qi; T Saeki; G Johnson; N Kim; F Ciardiello; M Shoyab; G Plowman; R Brandt
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-29       Impact factor: 11.205

8.  Expression of transforming growth factor alpha, amphiregulin and cripto-1 in human breast carcinomas.

Authors:  C F Qi; D S Liscia; N Normanno; G Merlo; G R Johnson; W J Gullick; F Ciardiello; T Saeki; R Brandt; N Kim
Journal:  Br J Cancer       Date:  1994-05       Impact factor: 7.640

  8 in total
  15 in total

1.  Heregulin-beta promotes matrix metalloproteinase-7 expression via HER2-mediated AP-1 activation in MCF-7 cells.

Authors:  Guogang Yuan; Lu Qian; Lun Song; Ming Shi; Dan Li; Ming Yu; Meiru Hu; Beifen Shen; Ning Guo
Journal:  Mol Cell Biochem       Date:  2008-07-04       Impact factor: 3.396

Review 2.  EGF-related peptides in the pathophysiology of the mammary gland.

Authors:  N Normanno; F Ciardiello
Journal:  J Mammary Gland Biol Neoplasia       Date:  1997-04       Impact factor: 2.673

Review 3.  The epidermal growth factor receptor in breast cancer.

Authors:  S B Fox; A L Harris
Journal:  J Mammary Gland Biol Neoplasia       Date:  1997-04       Impact factor: 2.673

4.  Full-length ADAMTS-1 and the ADAMTS-1 fragments display pro- and antimetastatic activity, respectively.

Authors:  Y-J Liu; Y Xu; Q Yu
Journal:  Oncogene       Date:  2006-04-20       Impact factor: 9.867

5.  The role of the tumor microenvironment in regulating angiogenesis.

Authors:  Randolph S Watnick
Journal:  Cold Spring Harb Perspect Med       Date:  2012-12-01       Impact factor: 6.915

6.  Amphiregulin-EGFR signaling regulates PTHrP gene expression in breast cancer cells.

Authors:  Jennifer L Gilmore; Jeffrey A Scott; Zhor Bouizar; Alex Robling; Sarah E Pitfield; David J Riese; John Foley
Journal:  Breast Cancer Res Treat       Date:  2007-09-20       Impact factor: 4.872

Review 7.  Amphiregulin as a novel target for breast cancer therapy.

Authors:  Nicole E Willmarth; Stephen P Ethier
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-04-25       Impact factor: 2.673

Review 8.  ErbB4/HER4: role in mammary gland development, differentiation and growth inhibition.

Authors:  Rebecca S Muraoka-Cook; Shu-Mang Feng; Karen E Strunk; H Shelton Earp
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-04-25       Impact factor: 2.673

9.  Antibody blockade of the Cripto CFC domain suppresses tumor cell growth in vivo.

Authors:  Heather B Adkins; Caterina Bianco; Susan G Schiffer; Paul Rayhorn; Mohammad Zafari; Anne E Cheung; Olivia Orozco; Dian Olson; Antonella De Luca; Ling Ling Chen; Konrad Miatkowski; Chris Benjamin; Nicola Normanno; Kevin P Williams; Matthew Jarpe; Doreen LePage; David Salomon; Michele Sanicola
Journal:  J Clin Invest       Date:  2003-08       Impact factor: 14.808

10.  Emerging roles of nodal and Cripto-1: from embryogenesis to breast cancer progression.

Authors:  Luigi Strizzi; Lynne-Marie Postovit; Naira V Margaryan; Elisabeth A Seftor; Daniel E Abbott; Richard E B Seftor; David S Salomon; Mary J C Hendrix
Journal:  Breast Dis       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.